Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1103 of 6351
-
Radiation plus two immunotherapy drugs shows promise in advanced cancers
Disease control CompletedThe main purpose of this study is to determine how best to combine hypofractionated radiotherapy, MEDI4736, and tremelimumab and to determine how safe and tolerable hypofractionated radiotherapy, MEDI4736, and tremelimumab are when given together in subjects with metastatic, mela…
Phase 1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Surgery may tame seizures in brain tumor patients
Disease control Recruiting nowBackground: Some people with brain tumors have seizures related to the tumor. This is called tumor-related epilepsy. Usually brain tumors are treated by removing as much of the brain tumor as possible without causing problems. Researchers think this may improve the outcome for p…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Vaccine-Chemo combo shows promise against spread prostate cancer
Disease control CompletedBackground: Metastatic castrate-sensitive prostate cancer is cancer that has spread beyond the prostate area. It can be controlled by lowering the amount of testosterone in the body. This is called androgen deprivation therapy (ADT). The vaccine PROSTVAC might help the immune sy…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug may free MDS patients from frequent blood transfusions
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of imetelstat sodium in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment in Phase 2 st…
Phase 2/3 • Sponsor: Geron Corporation • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a Drug-Vaccine combo delay leukemia in High-Risk patients?
Disease control CompletedThis randomized phase II trial studies how well ibrutinib works when given together with vaccine therapies in treating patients without clinical signs or indications that raise the possibility of a particular disorder or dysfunction (asymptomatic) who have high-risk chronic lymph…
Phase 2 • Sponsor: Jennifer Woyach • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Swallow a sponge to spot cancer early?
Diagnosis Recruiting nowThis study is to identify potential biomarkers for the early detection of Barrett's Esophagus, esophageal carcinoma (both adenocarcinoma and squamous cell carcinoma), and gastric cancer via sponge cytology.
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
New drug duo shows promise in tough lung cancer
Disease control CompletedThe purpose of the study is to define the safety and tolerability of this drug combination. The study will also define the response rate of patients with advanced and unresectable NSCLC.
Phase 1/2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for NF1 patients: drug shows promise against inoperable tumors
Disease control OngoingBackground: Neurofibromatosis type 1 (NF1) is a disorder that can cause plexiform neurofibromas (PNs). These are tumors that grow along nerves. Some PNs cause serious health problems. PNs often can t be operated on because of their large size, location, or number. There are no e…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo shows promise for rare genetic cancers
Disease control OngoingThis phase II MATCH treatment trial identifies the effects of trametinib and dabrafenib in patients whose cancer has genetic changes called BRAF V600 mutations. Dabrafenib may stop the growth of cancer by blocking BRAF proteins which may be needed for cell growth. Trametinib may …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Precision radiation may tame nerve tumors without surgery
Disease control CompletedHistorically, the management of schwannomas has relied primarily on observation, surgery, or conventional radiotherapy techniques. However, while surgery is curative, it carries significant risks-including postoperative complications, neurological deficits, and substantial morbid…
Sponsor: Hartmann Oncology Radiotherapy Group, France • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
Gene therapy shows promise for rare eye disease causing blindness
Disease control CompletedThe goal of this clinical trial is to assess the effectiveness of GS010, a gene therapy, in improving the visual outcome in participants with Leber Hereditary Optic Neuropathy (LHON) due to the G11778A ND4 mitochondrial mutation when vision loss is present for more than six month…
Phase 3 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New chemo cocktail aims to boost survival in kids with rare lymphoma
Disease control OngoingThe outcomes of children with lymphoblastic lymphoma (LBL) in China in the investigators' previous study were not unexpected. In this study, through further modification treatment protocols and strengthen domestic multicenter collaboration, the investigators try to improve surviv…
Phase 3 • Sponsor: Children's Cancer Group, China • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
AI boosts cataract surgery precision for severely nearsighted patients
Diagnosis Recruiting nowThis study aims to establish a multi-center artificial intelligence model for the accurate calculation of intraocular lens and its clinical application in highly myopic cataract, so as to improve the accuracy of the prediction of postoperative diopter in highly myopic cataract pa…
Sponsor: Shanghai High Myopia Study Group • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Could stem cells restore sight in damaged eyes?
Disease control Recruiting nowThis study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
Sponsor: MD Stem Cells • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a simple annual blood test shield cancer survivors from heart attacks and strokes?
Knowledge-focused CompletedThis observational study will evaluate whether annual low-density lipoprotein cholesterol (LDL-C) testing is associated with improved cardiovascular preventive care and a lower risk of cardiovascular events among cancer survivors. The study will use nationwide health insurance a…
Sponsor: Samsung Medical Center • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
New 'Bottom-Up' surgery for rectal cancer could mean faster recovery
Disease control CompletedStandard surgical treatment of mid and low rectal cancer is total mesorectal excision (TME). Originally performed by open surgery, TME demonstrated improved local control and reduced urogenital morbidity. Laparoscopic approach has been validated by several randomised controlled t…
Phase 3 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immune booster added to standard cancer care shows promise in early trial
Disease control OngoingThe purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for head and neck cancer. The standard of care treatment will include surgery followed by ra…
Phase 2 • Sponsor: Trisha Wise-Draper • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for hard-to-treat myeloma patients?
Disease control CompletedThis study is a Multicentre, Open-label, Phase II study of Daratumumab and Dexamethasone in MM patients. Eligible patients must have a symptomatic RRMM with a measurable disease, resistant or refractory to Bortezomib and Lenalidomide and Pomalidomide. There is no dose escalation…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New radiation technique aims to protect memory in lung cancer patients
Disease control CompletedThis randomized phase II/III trial studies how well whole-brain radiation therapy works and compares it with or without hippocampal avoidance in treating patients with small cell lung cancer that is found in one lung, the tissues between the lungs, and nearby lymph nodes only (li…
Phase 2/3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can stronger, targeted radiation beat brain metastases without Whole-Brain side effects?
Disease control OngoingSRS dose escalation for brain metastases in radiation-naïve patients will establish true tolerable doses, which may exceed the current standard doses. This may lead to an improvement in local control, patient survival, and/or quality-of life.
Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC